Investigational drug · Phase 3
IMU-838
Also called: Vidofludimus calcium
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Relapsing-Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
8
Any phase or sponsor naming "IMU-838"
First trial start
2019
Jan 28, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IMU-838", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsing-Remitting Multiple Sclerosis (RRMS)
- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
Approved drugs for the same conditions: Multiple sclerosis · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "IMU-838" as an intervention, largest first.
- Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisPivotal-lookingActive, not recruiting
Immunic AGIndustry
NCT05134441 · 1,121 participants · Start Nov 18, 2021 · Primary completion Nov 2026
Drug: IMU-838 tablets; Placebo matching IMU-838 tablets · For: Multiple Sclerosis
Sites: Phoenix, Arizona; West Hollywood, California; Bradenton, Florida · 103 sites in all
- Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple SclerosisPivotal-lookingActive, not recruiting
Immunic AGIndustry
NCT05201638 · 1,100 participants · Start Jan 12, 2022 · Primary completion Nov 2026
Drug: IMU-838 tablets; Placebo matching IMU-838 tablets · For: Multiple Sclerosis, Relapsing-Remitting
Sites: Altamonte Springs, Florida; Coral Springs, Florida; Yerevan, Armenia · 101 sites in all
- Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple SclerosisPivotal-lookingStatus unknown
Immunic AGIndustry
NCT05054140 · 450 participants (planned) · Start Sep 30, 2021 · Primary completion Jan 7, 2025
Drug: IMU-838; Placebo matching IMU-838 · For: Multiple Sclerosis
Sites: Coral Springs, Florida; Naples, Florida; Ormond Beach, Florida · 73 sites in all
- Phase 2 Dose-finding IMU-838 for Ulcerative ColitisPivotal-lookingTerminated
Immunic AGIndustry
NCT03341962 · 263 participants · Start Mar 15, 2018 · Primary completion Nov 16, 2022
Drug: IMU-838; Placebo · For: Ulcerative Colitis
Sites: Tucson, Arizona; Los Angeles, California; Ventura, California · 131 sites in all
- A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)Pivotal-lookingCompleted
Immunic AGIndustry
NCT04379271 · 234 participants · Start Jun 11, 2020 · Primary completion Jan 12, 2021
Drug: IMU-838 · For: COVID-19
Sites: Sofia, Bulgaria; Frankfurt, Germany; Hanover, Germany · 4 sites in all
- MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)Pivotal-lookingActive, not recruiting
Immunic AGIndustry
NCT03846219 · 210 participants · Start Jan 28, 2019 · Primary completion Apr 24, 2020
Drug: IMU-838 (30 mg/day); IMU-838 (45 mg/day) and 2 more · For: Relapsing-Remitting Multiple Sclerosis (RRMS)
Sites: Blagoevgrad, Bulgaria; Pleven, Bulgaria; Plovdiv, Bulgaria · 38 sites in all
University Hospitals Coventry and Warwickshire NHS TrustAcademic, hospital or other
NCT04516915 · 38 participants · Start Jun 15, 2020 · Primary completion May 20, 2022
Drug: IMU-838; Oseltamivir · For: Covid 19
Sites: Coventry, United Kingdom
Elizabeth CareyAcademic, hospital or other
NCT03722576 · 18 participants · Start Jun 17, 2019 · Primary completion Jun 30, 2020
Drug: Vidofludimus calcium · For: Primary Sclerosing Cholangitis
Sites: Phoenix, Arizona; Tempe, Arizona; Rochester, Minnesota
Newest research
PubMed records naming it or its code names, newest first.
- Multiple sclerosis: Advances in diagnosis, biomarkers, and disease management.
Grund E, Cross AH, Chahin S · J Neuroimmunol 2026
- Vidofludimus calcium for the treatment of multiple sclerosis: development rationale, mechanism of action, and early trial data.
Ondrus M, Fox RJ, Peelen E, et al. · Expert Opin Investig Drugs 2026
- DHODH Inhibitors Based on the Vidofludimus Scaffold Containing Carboxylic Acid Bioisosteres Exert a Superior Broad-Spectrum Antiviral Activity.
Herrmann A, Hahn F, Wangen C, et al. · J Med Chem 2026
- Inhibition of pyrimidine de novo synthesis fosters Treg cells and reduces diabetes development in models of Type 1 Diabetes.
Hipp H, Tondello C, Gmehling H, et al. · Mol Metab 2025
- Randomized adaptive assessment of post COVID syndrome treatments (RAPID): a study protocol for a multicenter, randomized, controlled adaptive platform trial of treatment options for Post Covid Syndrome (PCS) on patients physical function including the first intervention specific appendix RAPID_REVIVE (reducing inflammatory activity in patients with PCS).
Weipert L, Telgmann RG, Anton G, et al. · Trials 2025
- Vidofludimus Calcium in Patients With Moderate-to-Severe Ulcerative Colitis: A Randomized, Placebo-Controlled, Phase 2 Trial.
D'Haens G, Stardelova KG, Sadiku E, et al. · Clin Transl Gastroenterol 2025
Also in development for Relapsing-Remitting Multiple Sclerosis (RRMS)
- RocbrutinibLP-168, NWP-775Phase 36 trials
Guangzhou Lupeng Pharmaceutical Company LTD. · Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Mantle Cell Lymphoma
- ABP 692Phase 31 trial
Amgen · Relapsing-remitting Multiple Sclerosis (RRMS)
- BCD-281Phase 31 trial
Biocad · Relapsing-remitting Multiple Sclerosis (RRMS)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.